中国临床前和毒性研究

中国临床前和毒性研究外
临床前和毒性研究外包:现状
现状分析
现状分析与
分析与前景预测

Future Outlook of China Preclinical

and Toxicology Outsourcing Market

JZMed, Inc.
 Report Description

It has been well recognized in the global pharmaceutical industry that the R&D
productivity of discovering a new medicine has been low. The high failure rate in
various development stages has been the main factor that drives up the overall cost of
drug discovery effort; whereas the severe toxicity and safety concerns have been the
major causes of the high development failure. As all drug companies are vigorously
controlling the R&D cost, the high failure rate has become a controlling factor for them
to improve the efficiency and productivity of drug discovery and development. To
reduce the overall cost of drug development, eliminating un-developable drug candidates
and avoiding them being unnecessarily advanced to any late development stage have
become critical to all drug companies. As such, all drug companies are now conducting
extensive toxicology and safety pharmacology research for any drug candidates.

Although relatively young, the service capability of Chinese CROs in preclinical and
toxicology research has been significantly improved in the recent years. As China
possesses a number of advantages in preclinical and toxicology research, many drug
companies are attracted by the significant benefits of conducting this type of research in
the country.

To help these drug companies better understand the current state of this Chinese industry,
the report “Future Outlook of China Preclinical and Toxicology Outsourcing
Market” published by JZMed, Inc, a world renowned market research firm specialized in
Chinese pharmaceutical industry, provides them with the unique insights into the current
service capability and capacity of the Chinese preclinical and toxicology outsourcing
industry.

The report revealed the current structural composition and the latest developments of the
Chinese industry. By comparing the service capability and market size of the Chinese
industry with its counterparts in the world, the report also provides a clear picture of
where the Chinese industry currently stands in the global preclinical and toxicology
outsourcing industry.

More importantly, by analyzing both growth drivers and resistors of the future
development of the Chinese industry and the competitive landscape of the world
preclinical and toxicology outsourcing industry, the report also provides the clear picture
of the future development potential of this Chinese industry.

The report is a must-read book to all professionals in the industries of pharmaceutical,

biotechnology, financial investment and outsourcing service that are interested in the
China’s pharmaceutical outsourcing industry. It is also a valuable reference book to drug
regulatory agencies and other government agencies that are involved in strategic planning
for development of pharmaceutical industry in their own countries.
 Scope of the Report

It has been well recognized in the global pharmaceutical industry that the R&D
productivity of discovering a new medicine has been low. The high failure rate in
various development stages has been the main factor that drives up the overall cost of
drug discovery effort; whereas the severe toxicity and safety concerns have been the
major causes of the high development failure. As all drug companies are vigorously
controlling the R&D cost, the high failure rate has become a controlling factor for them
to improve the efficiency and productivity of drug discovery and development. To
reduce the overall cost of drug development, eliminating un-developable drug candidates
and avoiding them being moved to any late development stage have become critical to all
drug companies. As such, all drug companies are now conducting extensive toxicology
and safety pharmacology research for any drug candidates.

Although relatively young, the service capability of Chinese CROs in preclinical and
toxicology research has been significantly improved in the recent years. As China still
possesses a number of advantages in preclinical and toxicology research, many drug
companies are attracted to and become interested in conducting this type of research in
the country. To help these drug companies better understand the current state of this
Chinese industry, the report described this Chinese industry from four different aspects.

Chapter One analyzed in depth why toxicology and safety studies have become so
important in the modern drug discovery and development, what drug companies’ desire
to improve their R&D efficiency and productivity and what the outsourcing service
providers are doing to meet the requirements of the drug companies.

Chapter Two analyzed why it is the time to recognize China also as a favored outsourcing
destination for preclinical and toxicology research and, based on the analysis, pointed out
that preclinical and toxicology outsourcing might be the next hot wave in China
following the current widespread small molecule drug discovery outsourcing in the
country.

In Chapter Three, detailed description was provided to drug companies about what China
currently has and what Chinese CROs currently can do in terms of their service capability
and capacity.

In the Fourth Chapter, an in-depth analysis was conducted about all major drivers and
resistors determining the future growth of the Chinese industry. Based on the analysis,
the report then forecasted the market growth pace of the Chinese industry between 2010
and 2015 and the possible market value it could reach by 2015.

The report is a must-read book to all professionals in the industries of pharmaceutical,

biotechnology, financial investment and outsourcing service that are interested in the
China’s pharmaceutical outsourcing industry.
 About the Author

Jim J. Zhang, Ph. D.

Jim J. Zhang currently is president and managing director of JZMed, Inc., a leading
market research company that specializes in the Chinese pharmaceutical, biotechnology
and pharmaceutical outsourcing industries. Before founding the company, Jim worked
for nine years with Albany Molecular Research, Inc. (AMRI), a US-based and currently
one of the world largest CROs. During his tenure at AMRI Jim was responsible for
managing and overseeing multiple drug R&D projects that involved the international
cooperation of AMRI’s multiple sites (USA, Singapore and Hungary). He played key
roles in helping numerous pharma and biotech companies discover and develop a series
of drug candidates that later entered preclinical and clinical development including
advanced clinical trials. He was also the key contributor to the development of chemical
production process for several developmental drugs. Prior to pursuing his Ph.D. program
in the US, Jim worked for six years in a China-based CMO as process engineer and
developed production process for a number of pharma products.

Jim’s technical expertise spans from chemical process research and development to drug
discovery and development for viral infection, cancer, chronic obstructive pulmonary
disease (COPD) and cystic fibrosis. Currently he holds 18 patents. He is also the
principal author of 12 peer-reviewed research articles.

Jim has authored a series of research reports about Chinese pharmaceutical outsourcing
industry. He was also invited by a number of market research firms such as Business
Insights to author/co-author industry reports.

Jim received his master’s degree in Chemical Engineering from East China University of
Science & Technology (Shanghai), and his Ph.D. degree in Synthetic Organic Chemistry
from the University of Iowa. He also received additional trainings in Medicinal
Chemistry through working at Research Triangle Institute (Research Triangle Park, North
Carolina).
 Key Findings of the Report
The Chinese pharmaceutical outsourcing industry has been growing in an exponential
rate in the past decade. Most early established Chinese CROs almost all started with
chemistry service only. However, after having practiced for a few years, a number of
them have now also gained sufficient experience and skills in preclinical and
toxicology research.

The rapid development and growth of the Chinese preclinical and toxicology
outsourcing industry is, to a large extent, contributed by the entrance of a number of
multinational CROs that are attracted by the fast growth history and still huge future
growth potential of the Chinese industry. Their presence has greatly enhanced the
overall service capability of the Chinese industry.

Currently, there have been about 65 CROs in total, including the China
divisions/branches of those multinational CROs, in the Chinese preclinical and
toxicology outsourcing service industry. Combined together, they provide a wide
spectrum of services covering almost all areas of the preclinical and toxicology
research. One of the key features of the Chinese service industry is that most Chinese
CROs have non-human primates for in vivo efficacy testing and other
pharmacological property studies, which have become more and more important in
the modern preclinical and toxicology research.

Most China-based CROs have brand new, state-of-the-art preclinical research

facilities including animal vivaria. Currently, Chin has a capacity of more than one
million square-foot animal space. About another one million square-foot animal
facility is under construction.

China has started implementing the GLP standard for preclinical and toxicology
research since 2007, including the regulations on the use of animals in medical
research. As the FDA gradually recognizes the Chinese GLP standard, more and
more data generated in the laboratories of Chinese CROs are now accepted by the
agency.

Responding to the improvements, a large number of drug companies, both major

pharma and small biotech, have outsourced their preclinical and toxicology research
to China. After conducting drug discovery research in China for several years, the
China R&D centers of many major pharma companies have generated a number of
lead compounds in their pipelines which are ready to enter the next development
stage. They are currently expanding their R&D focus in China along the value chain,
from originally only discovery-focused research to now also including early
development.

Although the current outsourcing demands for preclinical and toxicology research
service are still relatively soft in China (and in the globe as well) compared with those
years before the financial crisis, in long term, these demands will be still strong. A
number of positive drivers, both globally and regionally and both internally and
externally, all determine the anticipated fast future growth of the Chinese industry.

Globally, as more major pharma companies will be implementing the strategy of

networked partnership and as a key stage of drug development, outsourcing demands
for preclinical and toxicology research will only become stronger and stronger.
Similarly, outsourcing demands by small biotech companies will also become
stronger as more and more of them now pursue virtual operation model, which
determines that they will mostly rely on CROs to fulfill their R&D work.

Regionally, as China will still possess a number of advantages even five to seven
years from now in preclinical and toxicology research over many of its competitors in
the world, drug companies from around the world will be attracted to conduct this
type of research in the country.

Internally, continually working with experienced multinational companies is steadily

improving the skills and experience of Chinese CROs, which will in turn attract more
drug companies to outsource to the country. The outsourcing service demand by the
local domestic Chinese drug companies is also expected to grow rapidly in the near
future as more and more Chinese drug companies are now embarked on innovative
drug research.

Externally, as many pharma companies have now recognized the power and
usefulness of the large talent pool in China, conducting drug R&D directly in China
can enhance their productivity. The fast development of the Chinese industry will
also attract more multinational CROs to enter the Chinese market in the near future,
which will further accelerate the development and growth of the Chinese industry.

In the past several years China has been recognized as one of the best places in the
world for small molecule drug discovery research. The country is currently also
emerging as one of the most favored places for preclinical and toxicology research as
well. It is therefore expected that the outsourcing service of preclinical and
toxicology research will be the next wave in China. Major pharma companies will be
looking for outsourcing or collaboration opportunities in China. They will also be
implementing the networked partnership strategy in China through partnering with
preferred local companies or research organizations.

JZMed thus forecasted that the Chinese preclinical and toxicology outsourcing
industry will likely grow in a CAGR of 27% for five years after 2010 and its market
value will likely reach more than $760 M by 2015.

As the fast growth of the Chinese industry attracts more multinational CROs to enter
the Chinese market, the current industry landscape of the Chinese preclinical and
toxicology service sector will soon be changed as the competition will rise rapidly.
For Chinese CROs to survive the anticipated competition, it is expected that more
consolidations within the Chinese industry will take place in the very near future.
 Key Features of the Report

The report analyzed in depth and described in detail the current structural
composition of the Chinese preclinical and toxicology outsourcing industry. Based
on the broad and in-depth analysis, it is the first time ever that the report revealed the
influence of the multinational service providers on the development and growth of the
Chinese preclinical and toxicology outsourcing industry.

It is also the first time that the report described in detail the current service capability
and capacity of the Chinese industry including the successful identification of the best
players of the Chinese industry, China-based CROs that are certified for GLP
compliance or accredited by the international organizations for their facilities.

It is the first time that the report provided a guide to world pharmaceutical and
biotech companies that are interested in outsourcing to China of what China currently
has and what Chinese CROs can do at this moment.

It is also the first time that the report analyzed in depth the R&D activities of major
pharma companies in China and the driving factors that attract them to China as well
as the outsourcing strategies they are implementing in the country. Based on these
analyses, the report then pointed out what the next outsourcing steps these major
pharma companies will likely take in the Chinese market.

The report analyzed and provided a detailed description of the latest development
trends in the world preclinical and toxicology outsourcing industry with focus on the
latest development of technologies, drug companies’ new desires and the evolving
services offered by global major CROs in the preclinical and toxicology outsourcing
industry.

The report also performed comparisons of the Chinese industry with its global
counterparts in terms of their service capability and industry and market sizes. It
provides a clear picture of where the Chinese industry currently stands in the world
industry.

By analyzing both in detail and in depth a series of drivers and resistors, the report
also revealed how the Chinese industry will likely develop and grow in the near
future and what market size it could reach as well as its possible market share in the
global industry.

One of the key features of the report is that it includes the detailed company profiles
of the top 30 best players in the Chinese preclinical and toxicology outsourcing
industry, including the detailed description of their service capability, features and
experience. Besides, the company profile also contains the detailed information of
their animal space capacity, features of their facilities and the disease models offered,
in addition to their detailed contact information.
 Your Questions Are Answered

The report provides detailed answers to a variety of questions many professionals are
constantly asking about the Chinese preclinical and toxicology outsourcing industry:

Why does toxicology study now become so important? How drug companies allocate
their R&D budget to this part? How much is the current global toxicology research
spending? How much of that is currently outsourced? How much toxicology
outsourcing is from major pharma and how much from small biotech?

What is the current market size of global preclinical and toxicology outsourcing?
How much does Chinese market account in this global outsourcing sector?

Why do pharma and biotech companies want to go to China for preclinical and
toxicology outsourcing? What are their intensions of outsourcing to China?

What advantages and disadvantages does China currently possess in preclinical and
toxicology outsourcing? How to compare China’s these advantages with its global
counterparts? Will China still have such advantages in the following five to seven
years?

What are Chinese CROs’ current service capability and capacity? Who are the best
players in the Chinese industry? How do the world major CROs influence the
development of this Chinese industry both in the past and in the future?

Who are the Western CROs that provide this type of outsourcing service in China?
How will their presence in China impact the development of the local Chinese CROs?
How will this trend affect the future development path of this Chinese industry?

Who are those world drug companies that are currently outsourcing preclinical and
toxicology research to China? Why is it the right time to recognize China also as a
favored outsourcing destination for preclinical and toxicology research?

How will the Chinese preclinical and toxicology outsourcing market develop in the
next five to seven years? How to compare it with the global preclinical and
toxicology market in the same time period? How to compare the market size and
service capability of the Chinese CROs in this sector with their global competitors
including both Western CROs and Indian CROs?
 Table of Contents

Scope of the Report

About Author
Executive Summary

Growing importance of preclinical and toxicology research in drug discovery and

development
Preclinical and toxicology outsourcing nears mature in China
Current service capability and capacity of Chinese preclinical and toxicology
outsourcing industry
Future outlook of preclinical and toxicology outsourcing in China

Chapter One: Growing Importance of Preclinical and Toxicology Research in Drug

Discovery and Development

Summary
1.1 Introduction
1.2 Drug safety has become the bottleneck limiting drug R&D productivity
1.2.1 Cost and efficiency of drug R&D have become key concerns to all drug
companies
1.2.2 In-depth analysis of the causes of high failure rate in drug R&D
1.2.3 Reducing attrition rate and improving R&D productivity have become high
priority to all drug companies
1.3 Changing models of drug R&D spending
1.3.1 New trend: Less R&D budget but more positive results have become high
priorities to all drug companies
1.3.2 More R&D budget is being reallocated to preclinical and toxicology
research
1. Analysis of the cost structure of entire drug R&D process
2. Reallocating more R&D budget to preclinical and toxicology research
1.4 Development of new technologies to more precisely probe toxicity of drug
candidates
1.5 Global major CROs developing new outsourcing services
1.6 Evolving of new trends in preclinical and toxicology outsourcing
1.6.1 New outsourcing models
1. Contracting out a whole block of R&D functions
2. Networked Partnership
3. Open source innovation
1.6.2 Destination of preclinical and toxicology outsourcing is shifting toward the
East

Chapter Two: Preclinical and Toxicology Outsourcing in China Nears Mature

Summary
2.1 Introduction
2.2 Preclinical and toxicology outsourcing in China: A short history
2.3 Preclinical and toxicology outsourcing service is fast developing in China
2.3.1 Rapid growth of the CRO pool in China
2.3.2 Extremely fast growth of Chinese preclinical and toxicology outsourcing
market
2.4 Rapid improvement of service capability of Chinese CROs in preclinical and
toxicology research
2.5 China has formally established a regulatory body for preclinical research and is
rapidly enhancing its capability
2.6 Growing importance of China to drug companies around the world for preclinical
and toxicology research
2.6.1 China’s advantages in preclinical research
1. Abundant animal species
2. Large, well-trained workforce
3. Cost effective advantage
2.6.2 New development trends of preclinical and toxicology outsourcing in China –
Entrance of growing numbers of multinational CROs: A series of case studies
2.7 Major pharma companies starting outsourcing preclinical and toxicology research in
China
2.7.1 Motivations of major pharma companies outsourcing preclinical and
toxicology research to China
2.7.2 Case studies: Latest examples of outsourcing and research collaborations
between major pharma companies and Chinese companies/research
organizations
2.8 Time to outsource preclinical and toxicology research to China nears mature

Chapter Three: Current Service Capability and Capacity of Chinese Preclinical

and Toxicology Outsourcing Industry

Summary
3.1 Introduction
3.2 Current key players of Chinese preclinical and toxicology outsourcing industry
3.3 Service capability of China-based CROs
3.3.1 Description of general service capability of China-based CROs
1. General description of research scopes of modern preclinical and
toxicology studies
a. Different focuses between preclinical and toxicology study
b. Main focuses of modern toxicology research
c. Difference and similarity between toxicology and safety pharmacology
research
2. General service capability of China-based CROs
3.3.2 Service capability of China-based CROs in in vitro/in vivo ADME/Tox studies
3.3.3 Service capability of China-based CROs in in vivo drug efficacy
determination
3.3.4 Service capability of China-based CROs in other related research areas
3.4 Current facility and capacity of China-based CROs
3.4.1 General features of the facilities of China-based CROs
3.4.2 Animal disease models offered by China-based CROs

Chapter Four: Future Outlook of Preclinical and Toxicology Outsourcing in China

Summary
4.1 Introduction
4.2 Future growth drivers of Chinese preclinical and toxicology outsourcing service
industry
4.2.1 Internal drivers
1. China will still possess numerous advantages in preclinical and toxicology
outsourcing before 2015
2. Improved service capability and quality
3. Government support
4. Entrance of world major CROs
5. Growing demands for outsourcing service by local domestic Chinese drug
companies
4.2.2 External drivers
1. Strong demands by major pharma companies for preclinical and
toxicology outsourcing
a. Globally, outsourcing demands for drug R&D especially preclinical
and toxicology research service will become stronger − Analysis on
latest outsourcing strategies implemented by major pharma companies
b. Regionally, outsourcing demands for Chinese preclinical and
toxicology research service by major pharma companies will also
become stronger
2. Strong outsourcing demands by small biotech companies for preclinical
and toxicology research service
4.3 Future growth resistors
4.4 Forecast of future development patterns of Chinese preclinical and toxicology
outsourcing industry
4.4.1 More competition
4.4.2 More consolidation
4.5 Future market growth forecast of Chinese preclinical and toxicology outsourcing
industry
4.5.1 Future market growth forecast of Chinese preclinical and toxicology
outsourcing industry
4.5.2 Comparison with global market
4.5.3 Comparison with Indian market

Company Profile: Top 30 China-based Best CROs Providing Preclinical

and Toxicology Research Service

Appendix
Appendix I. Research Methodology
Appendix II. About JZMed, Inc.

List of Tables

Table 1. Statistic distribution of failure rate in each development stage of drug R&D
Table 2. Factors contributing to high failure rates in drug development
Table 3. Global drug R&D spending in the past five years (2005 to 2009)
Table 4. Cost analysis of each development stage of drug R&D process
Table 5. Benefits of reallocating drug R&D budget to preclinical and toxicology research
Table 6. China-based CROs (or research organizations) accredited by AAALAC
Table 7. Classifications and features of China-based preclinical and toxicology CROs
(Including representative companies of each class)
Table 8. Current market value and its growth history of Chinese preclinical and
toxicology outsourcing service industry
Table 9. Current market value and growth history of global preclinical and toxicology
outsourcing service industry
Table 10. Growth of the market share of Chinese preclinical and toxicology outsourcing
industry in the market value of global preclinical and toxicology outsourcing
industry
Table 11. Representative Chinese organizations that have obtained GLP certificate from
the SFDA
Table 12. China’s advantages in preclinical and toxicology research
Table 13. Comparison of labor cost in various locations of the world (FTE rate)
Table 14. Comparison of feasibility and advantages between conducting small molecule
drug discovery and preclinical/toxicology research in China
Table 15. List of top 30 best CROs in Chinese preclinical and toxicology outsourcing
industry
Table 16. Founder classification of top 30 China-based best CROs
Table 17. Detailed description of research scopes of preclinical and toxicology studies
Table 18. Scope of modern in vitro and in vivo toxicology research
Table 19. Type of preclinical and toxicology research services offered by China-based
CROs
Table 20. Key service features of each selected top CRO in China
Table 21. List of selected top China-based CROs and their detailed services in in vitro/in
vivo DMPK/ADME studies
Table 22. List of selected top China-based CROs and their services in toxicology study
Table 23. List of selected top China-based CROs offering safety pharmacology service
Table 24. List of selected top China-based CROs and their services in in vivo efficacy
testing
Table 25. List of selected top China-based CROs and their services in in vivo
pharmacology
Table 26. List of China-based CROs and their services in in vitro biological assays
Table 27. List of China-based CROs providing bio-analytical services
Table 28. List of China-based CROs providing biomarker-related services
Table 29. Key features of the selected top China-based CROs’ facilities
Table 30. Current animal space capacity of selected top China-based CROs
Table 31. List of China-based CROs possessing special animal disease models
Table 32. Advantages China will still possess before 2015
Table 33. Comparison of labor cost in countries around the world in the next seven years
(FTE rate)
Table 34. Comparison of cost saving (%) between China and other countries
(at present and by 2015)
Table 35. Market growth forecast of Chinese preclinical and toxicology outsourcing
service industry
Table 36. Market growth forecast of global preclinical and toxicology outsourcing
industry
Table 37. Forecasted growth of the market share of Chinese preclinical and toxicology
outsourcing service industry in the same industry of the globe
Table 38. Market growth forecast of Indian preclinical and toxicology outsourcing
service industry and comparison with its Chinese counterpart

List of Figures

Figure 1. Value chain of drug discovery and development

Figure 2. Driving factors forcing the toxicology research moved to discovery and early
development stages
Figure 3. New technology development trends in preclinical and toxicology research
Figure 4. Market growth trend of Chinese preclinical and toxicology outsourcing service
industry
Figure 5. Market growth trend of global preclinical and toxicology outsourcing service
industry
Figure 6. Key factors that facilitated Chinese preclinical and toxicology outsourcing
service industry to weather the current financial crisis
Figure 7. Key factors attracting drug companies to conduct preclinical and toxicology
research in China
Figure 8. Motivations of major pharma companies outsourcing preclinical and toxicology
research to China
Figure 9. Outsourcing strategies and practices currently implemented by major pharma
companies in China
Figure 10. Comparison of labor cost increase in China with other countries
(from 2009 to 2015)
Figure 11. Cost saving comparison (%) between China and other countries
(in 2010 and 2015, respectively)
Figure 12. Government plans to promote Chinese biopharma industry
Figure 13. Impacts of the latest mergers and acquisitions between experienced
multinational CROs and their Chinese counterparts on the future development
of Chinese preclinical and toxicology outsourcing service industry
Figure 14. Factors motivating major pharma companies to pursue more outsourcing in
drug discovery, preclinical and toxicology research
Figure 15. Current development trend of global small molecule drug discovery
outsourcing
Figure 16. Current R&D situation of major pharma companies in China
Figure 17. Analysis of the future outsourcing demands for Chinese preclinical and
toxicology research service by major pharma companies
Figure 18. Forecasted market growth trend of Chinese preclinical and toxicology
outsourcing service industry
Figure 19. Forecasted market growth trend of global preclinical and toxicology
outsourcing service industry
Figure 20. Forecasted market share growth of Chinese preclinical and toxicology
outsourcing industry in global preclinical and toxicology outsourcing industry
Figure 21. Forecasted market growth trend of Indian preclinical and toxicology
outsourcing service industry

List of Case Studies

Case Study 1. Drug R&D would not be that costly if failure rate could be reduced
Case Study 2. Biomarkers have become a hot outsourcing area in toxicology research
Case Study 3. Molecular imaging also becoming an important tool in preclinical as well
as toxicology research
Case Study 4. Growing importance of epigenomics in assessment of drug safety and
drug-induced toxicity
Case Study 5. Major CROs all embarked on biomarker service
Case Study 6. Charles River expanding discovery service
Case Study 7. Partnership formed to promote predictive toxicology service
Case Study 8. Alliance formed to develop drug toxicity screening assays
Case Study 9. Examples of major pharma companies increasingly utilizing external
resources
Case Study 10. Examples of Western pharma companies outsourcing preclinical and
toxicology research to Asian countries
Case Study 11. A unique class of workforce in China: Chinese returnees and its current
state
Case Study 12. Frontier Biosciences entered Chinese market
Case Study 13. Bridge Lab established, expanded and eventually sold its China division
Case Study 14. Charles River entering Chinese market through acquiring a local Chinese
CRO and currently aggressively looking for expansion
Case Study 15. Covance planning to offer preclinical outsourcing service in China
Case Study 16. Astra-Zeneca outsourcing preclinical and toxicology research to Chinese
CROs
Case Study 17. Astra-Zeneca expanded discovery contract with BioDuro
Case Study 18. Pfizer signed in vitro ADME/Tox outsourcing contract with WuXi
AppTec
Case Study 19. Johnson &Johnson forging close relationship with WuXi AppTec
Case Study 20. Attempted acquisition of WuXi AppTec by Charles River
Case Study 21. More recent merger and acquisition examples between Chinese CROs
and their multinational counterparts
Case Study 22. Domestic Chinese drug companies increasingly collaborating with local
CROs for drug R&D
Case Study 23. Examples of pharma company outsourcing all drug discovery research
Case Study 24. Global pharmaceutical outsourcing: An outlook of its future development
Case Study 25. Major pharma companies have now recognized the power and usefulness
of the large talent pool in China
Case Study 26. More R&D-focused biotech companies adopting virtual operation model
Case Study 27. Merger between two Chinese CROs
Case Study 28. Alliance formed between two China-based CROs
Case Study 29. Indian CROs’ capability in preclinical and toxicology outsourcing service
 About JZMed, Inc.

JZMed, Inc. (www.jzmedi.com) is a leading market research firm that specializes in

Chinese pharmaceutical, biotechnology and outsourcing service industries. The
company’s primary focus is to provide intelligence services to global pharmaceutical and
biotech companies to help them tap the resources in the Chinese pharmaceutical industry
and explore the opportunities in the Chinese pharmaceutical market. Meanwhile, it also
provides assistance to these companies to facilitate their entrance into the Chinese
pharmaceutical market or collaborations with any Chinese companies. The company has
a network of preferred pharma and biotech companies in China.

So far JZMed has provided this type of services to a variety of companies worldwide,
including six of world top twenty pharma companies, more than ten biotech companies,
more than fifteen professional outsourcing service companies (both CROs and CMOs)
and more than twenty investment companies/banks including the largest ones in the Wall
Street.
 To Order

Information about the Report:

Author: Jim J. Zhang, Ph.D.

Publisher: JZMed, Inc.
Total number of pages: 188
Date published: October, 2010

Pricing:

For single user: $2,895/PDF copy;

For department licensing: $5,795 (PDF copy only)
For enterprise-wide licensing: $8,695 (PDF copy only)

Readers interested in the report can contact JZMed, Inc. at order@jzmedi.com.

Report ordering can also be processed through PayPal, secured online payment, directly
at the website of JZMed, Inc. (www.jzmedi.com). All major credit cards are accepted.